Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for ...

It has been about a month since the last earnings report for Nektar Therapeutics (NKTR). Shares have lost about 38.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Nektar Therapeutics has recently seen its Consensus Analyst Price Target rise from $96.17 to $101.17. This increase comes as bullish analysts respond to strong Phase 2b results for rezpegaldesleukin ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar Therapeutics is extending its cash runway with the sale of one of its two main ...

In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash ...

The latest price target for Nektar Therapeutics (NASDAQ:NKTR) was reported by B. Riley Securities on September 23, 2025. The analyst firm set a price target for $105.00 expecting NKTR to rise to ...

What: Shares of Nektar Therapeutics,a small-cap biopharma that developsdrug candidates using its PEGylation and polymer conjugate technology, saw its shares skyrocket by more than 30% duringthe month ...

Nektar (NASDAQ:NKTR) is reportedly suing former partner Eli Lilly (NYSE:LLY) for allegedly miscalculating key clinical trial data for Nektar's dermatology and immunology drug candidate Rezpeg. Nektar ...

Nektar Therapeutics (NASDAQ:NKTR) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Nektar ...